The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program.
about
Current controversies in data monitoring for clinical trials.Independent academic Data Monitoring Committees for clinical trials in cardiovascular and cardiometabolic diseases.Advantages of Bayesian monitoring methods in deciding whether and when to stop a clinical trial: an example of a neonatal cooling trial.Publishing interim results of randomised clinical trials in peer-reviewed journals.The stratified win ratio.
P2860
The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
The data monitoring experience ...... and morbidity (CHARM) program.
@ast
The data monitoring experience ...... and morbidity (CHARM) program.
@en
type
label
The data monitoring experience ...... and morbidity (CHARM) program.
@ast
The data monitoring experience ...... and morbidity (CHARM) program.
@en
prefLabel
The data monitoring experience ...... and morbidity (CHARM) program.
@ast
The data monitoring experience ...... and morbidity (CHARM) program.
@en
P2093
P1476
The data monitoring experience ...... and morbidity (CHARM) program.
@en
P2093
Charles H Hennekens
Duolao Wang
Lars Wilhelmsen
Stuart Pocock
P304
P356
10.1016/J.AHJ.2004.10.038
P407
P577
2005-05-01T00:00:00Z